Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $12.6900 (-7.3%) ($12.6600 - $13.8600) on Mon. Apr. 27, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.4% (three month average) | RSI | 73 | Latest Price | $12.6900(-7.3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 13.2% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.7% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-14%) TLT(-1%) IYT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.7% (StdDev 7.4%) | Hourly BBV | 0 () | Intraday Trend | -8.3% | | | |
|
5 Day Moving Average | $12.75(-0.47%) | 10 Day Moving Average | $12.01(5.66%) | 20 Day Moving Average | $10.92(16.21%) | To recent high | -20.6% | To recent low | 77.7% | Market Cap | $1.607b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |